HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eder, M. Articles by Ganser, A. Search for Related Content PubMed PubMed Citation Articles by Eder, M. Articles by Ganser, A.

IL-3 in the Clinic

Department of Hematology and Oncology, Hannover Medical School, Hannover, Germany

Key Words. Interleukin-3 • Clinical study • Therapy

Dr. Matthias Eder, Department of Hematology and Oncology, Hannover Medical School, D-30623 Hannover, Germany.

Since the cloning of human interleukin 3 (IL-3) in 1986 [1] and the demonstration of its proliferative effects on multiple hematopoietic progenitor cells, IL-3 has been widely studied to treat different states of bone marrow failure or hematologic malignancies, to mobilize or expand hematopoietic progenitor cells for transplantation, and to support engraftment after bone marrow transplantation. However, no condition for the clinical use of IL-3 has been established so far despite its theoretical advantages as an early-acting cytokine and in contrast to erythropoietin (EPO), G-CSF, or GM-CSF all of which have already been approved for several clinical modalities. Here we shortly review our current knowledge about the effects of IL-3 on the molecular and cellular level, summarize recent clinical studies with IL-3, and discuss further perspectives for the use of this cytokine.

This article has been cited by other articles:

				M. P. Brown, T. Nosaka, R. A. Tripp, J. Brooks, J. M.A. van Deursen, M. K. Brenner, P. C. Doherty, and J. N. Ihle Reconstitution of Early Lymphoid Proliferation and Immune Function in Jak3-Deficient Mice by Interleukin-3 Blood, September 15, 1999; 94(6): 1906 - 1914. [Abstract] [Full Text] [PDF]

				Y. Parada, L. Banerji, J. Glassford, N. C. Lea, M. Collado, C. Rivas, J. L. Lewis, M. Y. Gordon, N. S. B. Thomas, and E. W.-F. Lam BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 Expression J. Biol. Chem., June 22, 2001; 276(26): 23572 - 23580. [Abstract] [Full Text] [PDF]